Terren Peizer founded Hythiam in 2003. Recognizing that advances in scientific research definitively established alcohol and drug addiction as physiological chronic diseases — not psychological, sociological or personality disorders — Peizer launched Hythiam.
Prior to forming Hythiam, Peizer founded and served as Chairman and CEO of Clearant, Inc., a biotechnology company that is a leader in pathogen inactivation solutions. Peizer has served as President and Vice Chairman of Hollis-Eden Pharmaceuticals and Chairman of the Board of Cray, Inc. — the supercomputing industry leader. He remains the largest beneficial shareholder of Cray, Inc. He also has been among the largest beneficial shareholders and senior executives at several other technology and biotechnology companies.
Peizer has assisted companies with assembling management teams, boards of directors and scientific advisory boards, and formulating business and financial strategies — including investor and public relations and capital formation. Peizer has a background in venture capital, mergers and acquisitions, investing, and corporate finance. He held senior executive positions with the investment banking firms Goldman Sachs, First Boston and Drexel Burnham Lambert.
Chuck Timpe
Chief Financial Officer
Chuck Timpe is a senior financial executive with more than 30 years' experience in the healthcare industry. Prior to joining Hythiam, Timpe was CFO of Protocare, Inc., a clinical research and pharmaceutical outsourcing company that merged with Radiant Research, Inc., creating the country's largest clinical research site management organization. Timpe has served as Treasurer and Corporate Controller for American Medical International (now Tenet Healthcare) and a Senior Audit Manager in the Arthur Andersen healthcare practice. He also founded two healthcare industry management-consulting firms. Timpe currently serves as a Director and Chairman of the Audit Committee for IPC - The Hospitalist Company, a physician specialty practice business. He has served on the boards of a medical group, a community hospital and an open MRI facility.
Richard A. Anderson
Senior Executive Vice President
With more than a decade of experience in business development, strategic planning and financial management, Anderson is responsible for overseeing the contractual aspects of Hythiam’s business while managing corporate infrastructure requirements. Prior to arriving at Hythiam he was a Director and the Chief Financial Officer of Clearant, Inc., a biotechnology company, and served as Chief Financial Officer of Intellect Capital Group. Anderson also served as a consultant to various developmental and emerging growth companies. Anderson was with the Price Waterhouse accounting firm, most recently as a Director and Founding Member of PriceWaterhouseCoopers Transaction Support Group, where he was involved in operational and financial due diligence, valuations, and structuring for technology companies.
Chris Hassan
Senior Executive Vice President
Chris Hassan currently manages Hythiam’s marketing and sales operations. He has over 20 years of healthcare management experience in sales, marketing and strategic and product development positions, and he spent the last eight years focused on the treatment of substance abuse. Prior to joining Hythiam, he was responsible for the founding and development of the commercial team responsible for the U.S. launch of Suboxone™ for opiate dependence. He has also been involved with the development of novel products for the treatment of alcohol and opiate dependence at Drug Abuse Sciences, and has held management positions at Parke-Davis/Pfizer and Bayer pharmaceuticals.
